Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.02
Ask: 6.50
Change: -0.15 (-2.54%)
Spread: 1.48 (29.482%)
Open: 5.91
High: 0.00
Low: 0.00
Prev. Close: 5.91
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Angle revenue up; Synairgen, Bango loss widens

Thu, 29th Sep 2022 20:30

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Angle PLC - Surrey, England-based medical diagnostics company - Pretax loss in the first half of 2022 widens to GBP10.5 million from GBP8.7 million, due to "a planned investment." Revenue rises to GBP419,000 from GBP296,000, "driven by research use sales of the Parsortix system along with an initial contribution from the pharma services business, including both clinical trial services and bespoke assay development." Expects its first FDA clearance to "positively impact all areas" of its business going forward.

----------

Bango PLC - Cambridge-based mobile commerce company - Pretax loss widens to USD1.2 million in the first half of 2022 from USD617,000 a year before. Administrative expenses rise to USD10.4 million from USD9.2 million. Revenue grows to USD10.8 million versus USD9.9 million. Attributes this to its "virtuous circle strategy" and investment in research and development, which continues to generate strong growth. Believes it is well positioned to continue taking market share.

----------

XLMedia PLC - Henley-on-Thames-based digital publisher - Pretax loss widens to USD1.7 million in the first half of 2022 from USD439,000 a year ago. Sales and marketing costs jump to USD16.2 million from USD7.3 million. Revenue rises 48% to USD44.5 million from USD32.2 million. Attributes this to new partnerships throughout the period. Expects full-year adjusted earnings before interest, tax, depreciation, and amortization is broadly in line with the prior year, returning to growth in 2023.

----------

Maintel Holdings PLC - London-based cloud and managed service specialist - Pretax loss in the six months to June 30 dives to GBP575,000 from a profit of GBP3.8 million a year before. Revenue falls 13% to GBP46.7 million from GBP53.5 million. Blames this on hardware supply-chain problems that significantly hurt revenue. Notes that supply chains are not expected to normalise until the second quarter of 2023. Remains confident that it will return to organic growth as global supply chains normalise.

----------

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Pretax loss for the half-year to June 30 shrinks to GBP14.0 million from GBP38.9 million, as research and development expenditure falls to GBP11.1 million from GBP36.9 million. Explains that expenditure on the phase 3 Sprinter trial and manufacturing activities reduced.

----------

Armadale Capital PLC - London-based Africa-focused natural resource projects investor - Pretax loss in the first half of 2022 widens to GBP152,000 from GBP27,000 a year before. Records an unrepeated gain of GBP139,000 in the prior period.

----------

Arc Minerals Ltd - base metals exploration company focused in Africa - Pretax loss in the first half widens to GBP8.5 million from GBP3.6 million a year before. Attributes this to an expense of GBP6.8 million, due to the Zamsort/Handa restructuring, after transferring Zamsort assets and liabilities to Handa Resources Ltd.

----------

Orosur Mining Inc - Toronto-based mineral exploration & development company focused on South America - Net loss for continued operations in the year to May 31 narrows to USD1.4 million from USD1.7 million a year before. Gain on fair value of warrants increases to USD1.6 million from USD627,000. "The handing over of operational control at Anza in late 2021, and a strong balance sheet, have freed up our skilled South American team to examine investment in new projects. The addition of our Ariquemes tin project in Brazil, and of the El Pantano gold/silver project in Argentina have transformed the company into a well-balanced minerals exploration company," Executive Louis Castro comments.

----------

VPC Specialty Lending Investments PLC - invests in asset-backed loans to businesses originated by non-bank lenders - Net asset value as at June 30 falls to 105.51 pence from 114.14p as at December 31. Share price on the same date falls to 83.40p from 92.20p as at December 31. Delivers a total return of negative 4.1%. Blames this on an unpredictable and volatile macroeconomic environment. Declares quarterly dividends totalling 4.00 pence per share. Remains in a period of heightened uncertainty, with inflation still at "worryingly high levels".

----------

Crossword Cybersecurity PLC - Richmond, England-based cybersecurity solutions company - Pretax loss in the first half of 2022 widens to GBP2.3 million from GBP1.5 million a year before. Administrative expenses grow to GBP2.1 million from GBP1.5 million. Revenue grows 85% to GBP1.5 million versus GBP824,923. Attributes this to the integration of three companies with strong underlying Software as a service and services recurring revenue. Projects revenue growth of roughly 75% to GBP4 million in 2022, driven by organic growth and already completed acquisitions.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
9 Sep 2020 12:23

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

Read more
8 Sep 2020 19:32

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

Read more
8 Sep 2020 15:16

Synairgen upbeat on latest data from SNG001 trials

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.

Read more
21 Jul 2020 15:51

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

Read more
20 Jul 2020 20:23

COVID SCIENCE-Multiple vaccine candidates show early promise; inhaled interferon helps severe COVID-19 patients

By Nancy LapidJuly 20 (Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Early tests of COVID-19 ...

Read more
20 Jul 2020 16:55

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

Read more
20 Jul 2020 11:54

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Read more
20 Jul 2020 09:10

UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasm (Recasts, adds comment from CEO and academic expert)By Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold...

Read more
20 Jul 2020 09:10

REFILE-UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

(Refiles to correct spelling in the media identifier)* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasmBy Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold ...

Read more
20 Jul 2020 09:10

UPDATE 1-Synairgen shares soar as drug shows lower risk of severe COVID-19 cases

(Adds details on the trial, shares)July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdo...

Read more
20 Jul 2020 07:56

Europe open: Stocks reverse early losses, healthcare leads

(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.

Read more
20 Jul 2020 07:56

Synairgen's drug shows reduced risk of severe disease in COVID-19 patients

July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.The trial, which used in...

Read more
20 Jul 2020 07:20

Synairgen treatment reduces risk of 'severe' Covid-19 by 79%

(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.

Read more
22 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Jun 2020 17:59

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.